The effects of Suprathel® versus a calcium alginate on pain perception and comfort in split-thickness skin graft donorsites.

The effects of Suprathel® versus a calcium alginate on pain perception and comfort in split-thickness skin graft donorsites. - Suprathel® versus a calcium alginate on the STSG donorsite.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON35254

Enrollment

120

Registered

2010-02-25

Start date

2010-07-19

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Donor wound skin transplant wound

Interventions

After randomization half of the number of donor sites will be bound with Suprathel® and the other half with a calcium alginate.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: The patient is 18 years or above. A STSG will be harvested from the patient's upperleg. The patient signed the informed consent form.

Exclusion criteria

Exclusion criteria: The STSG is harvested from any area other then the upperleg. The STSG is harvested from a previous donorsite. The patient has any mental limitation, which will compromise parts of the research. The patient has any known allergies for one of the wound dressings or their ingredients. The patient is not able to perceive pain, due to any sensibel impairment. On medical grounds, the patient should not be treated with adrenaline dressings.

Design outcomes

Primary

Measure	Time frame
The main study parameter is the difference in pain experience and comfort between Suprathel® and a calcium alginate.	—

Secondary

Measure	Time frame
Secondary study parameters are the differences in costs, scarring and itching of scar tissue between Suprathel® and a calcium alginate.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)